3 years ago

Incidence and prognostic implications of late bleeding events after percutaneous mitral valve repair

Tomás Benito-gonzález, Rodrigo Estévez-loureiro, Armando Pérez De Prado, Carlos Minguito-carazo, Samuel Del Castillo García, Carmen Garrote-coloma, Ignacio Iglesias-gárriz, David Alonso-rodríguez, Javier Gualis Cardona, Carlos Cuellas Ramón, María López Benito, Julia Vidán Estévez, Felipe Fernández-vázquez

Publication date: December 2018

Source: IJC Heart & Vasculature, Volume 21

Author(s): Tomás Benito-González, Rodrigo Estévez-Loureiro, Armando Pérez de Prado, Carlos Minguito-Carazo, Samuel del Castillo García, Carmen Garrote-Coloma, Ignacio Iglesias-Gárriz, David Alonso-Rodríguez, Javier Gualis Cardona, Carlos Cuellas Ramón, María López Benito, Julia Vidán Estévez, Felipe Fernández-Vázquez


MitraClip is an established therapy for patients with mitral regurgitation (MR) that are considered of high-risk or inoperable. However, late bleeding events (BE) after hospital discharge and their impact on prognosis in this cohort of patients have been poorly investigated. Our purpose is to address the incidence, related factors and clinical implications of BE after hospital discharge in patients treated with MitraClip.


Prospective registry of all consecutive patients (n = 80) who underwent MitraClip implantation in our Institution between June 2014 and December 2017. BE were defined according to MVARC definitions. A combined clinical end-point including admission for heart failure (HF) and all-cause mortality was established to analyze prognostic implications of BE.


During a median follow up of 523.5 days, 41 BE were reported in 21 patients. Atrial fibrillation (AF, HR 4.54, CI95% 1.20–17.10) and combined antithrombotic therapy at discharge (HR 3.52, CI95% 1.03–11.34) were independently associated with BE. In the study period, 15 (18.8%) patients died, 20 (25%) were admitted for HF and 29 (36.3%) presented the combined end-point. After multivariable adjustment BE remained independently associated with an adverse outcome (HR 3.80, CI 95% 1.66–8.72). In the subgroup of patients with AF, HAS-BLED score was higher among subjects with BE (3.1 ± 1.3 vs 2.1 ± 0.9, p = 0.003). HAS-BLED score had a significant discrimination power for the occurrence BE (AUC: 0.677 [0.507–0.848]) in this subgroup.


BE are common after MitraClip and are associated with an impaired outcome. Strategies to reduce bleeding events are paramount in this cohort of patients.

You might also like
Discover & Discuss Important Research

Keeping up-to-date with research can feel impossible, with papers being published faster than you'll ever be able to read them. That's where Researcher comes in: we're simplifying discovery and making important discussions happen. With over 19,000 sources, including peer-reviewed journals, preprints, blogs, universities, podcasts and Live events across 10 research areas, you'll never miss what's important to you. It's like social media, but better. Oh, and we should mention - it's free.

  • Download from Google Play
  • Download from App Store
  • Download from AppInChina

Researcher displays publicly available abstracts and doesn’t host any full article content. If the content is open access, we will direct clicks from the abstracts to the publisher website and display the PDF copy on our platform. Clicks to view the full text will be directed to the publisher website, where only users with subscriptions or access through their institution are able to view the full article.